Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin

D.D. Karp; M.N. Pollak; R.B. Cohen; P.D. Eisenberg; P. Haluska; D. Yin; A. Lipton; L. Demers; K. Leitzel; M.L. Hixon; Leonardus Wendelinus Mathias Marie Terstappen; L. Garland; L.G. Paz-Ares; F. Cardenal; A. Gualberto

doi:10.1097/JTO.0b013e3181ba2f1d

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin

D.D. Karp, M.N. Pollak, R.B. Cohen, P.D. Eisenberg, P. Haluska, D. Yin, A. Lipton, L. Demers, K. Leitzel, M.L. Hixon, Leonardus Wendelinus Mathias Marie Terstappen, L. Garland, L.G. Paz-Ares, F. Cardenal, A. Gualberto

Medical Cell Biophysics

Research output: Contribution to journal › Article › Academic › peer-review

56 Citations (Scopus)

Original language	Undefined
Pages (from-to)	1397-1403
Journal	Journal of thoracic oncology
Volume	4
Issue number	11
DOIs	https://doi.org/10.1097/JTO.0b013e3181ba2f1d
Publication status	Published - 2009

Keywords

METIS-259828

Access to Document

10.1097/JTO.0b013e3181ba2f1d

Cite this

Karp, D. D., Pollak, M. N., Cohen, R. B., Eisenberg, P. D., Haluska, P., Yin, D., Lipton, A., Demers, L., Leitzel, K., Hixon, M. L., Terstappen, L. W. M. M., Garland, L., Paz-Ares, L. G., Cardenal, F., & Gualberto, A. (2009). Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin. Journal of thoracic oncology, 4(11), 1397-1403. https://doi.org/10.1097/JTO.0b013e3181ba2f1d

Karp, D.D. ; Pollak, M.N. ; Cohen, R.B. ; Eisenberg, P.D. ; Haluska, P. ; Yin, D. ; Lipton, A. ; Demers, L. ; Leitzel, K. ; Hixon, M.L. ; Terstappen, Leonardus Wendelinus Mathias Marie ; Garland, L. ; Paz-Ares, L.G. ; Cardenal, F. ; Gualberto, A. / Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin. In: Journal of thoracic oncology. 2009 ; Vol. 4, No. 11. pp. 1397-1403.

@article{a8ea9cfd77c34fc3ae8b32986e6b50b3,

title = "Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin",

keywords = "METIS-259828",

author = "D.D. Karp and M.N. Pollak and R.B. Cohen and P.D. Eisenberg and P. Haluska and D. Yin and A. Lipton and L. Demers and K. Leitzel and M.L. Hixon and Terstappen, {Leonardus Wendelinus Mathias Marie} and L. Garland and L.G. Paz-Ares and F. Cardenal and A. Gualberto",

year = "2009",

doi = "10.1097/JTO.0b013e3181ba2f1d",

language = "Undefined",

volume = "4",

pages = "1397--1403",

journal = "Journal of thoracic oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "11",

}

Karp, DD, Pollak, MN, Cohen, RB, Eisenberg, PD, Haluska, P, Yin, D, Lipton, A, Demers, L, Leitzel, K, Hixon, ML, Terstappen, LWMM, Garland, L, Paz-Ares, LG, Cardenal, F & Gualberto, A 2009, 'Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin', Journal of thoracic oncology, vol. 4, no. 11, pp. 1397-1403. https://doi.org/10.1097/JTO.0b013e3181ba2f1d

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin. / Karp, D.D.; Pollak, M.N.; Cohen, R.B.; Eisenberg, P.D.; Haluska, P.; Yin, D.; Lipton, A.; Demers, L.; Leitzel, K.; Hixon, M.L.; Terstappen, Leonardus Wendelinus Mathias Marie; Garland, L.; Paz-Ares, L.G.; Cardenal, F.; Gualberto, A.

In: Journal of thoracic oncology, Vol. 4, No. 11, 2009, p. 1397-1403.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin

AU - Karp, D.D.

AU - Pollak, M.N.

AU - Cohen, R.B.

AU - Eisenberg, P.D.

AU - Haluska, P.

AU - Yin, D.

AU - Lipton, A.

AU - Demers, L.

AU - Leitzel, K.

AU - Hixon, M.L.

AU - Terstappen, Leonardus Wendelinus Mathias Marie

AU - Garland, L.

AU - Paz-Ares, L.G.

AU - Cardenal, F.

AU - Gualberto, A.

PY - 2009

Y1 - 2009

KW - METIS-259828

U2 - 10.1097/JTO.0b013e3181ba2f1d

DO - 10.1097/JTO.0b013e3181ba2f1d

M3 - Article

VL - 4

SP - 1397

EP - 1403

JO - Journal of thoracic oncology

JF - Journal of thoracic oncology

SN - 1556-0864

IS - 11

ER -